Try our corporate solution for free!
(212) 419-8286

Pfizer's total revenue 2006-2020

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2020, the company's total revenue was about 42 billion U.S. dollars. This is a significant decrease compared to the year before and, of course, a consequence of the spin-off of the company's Upjohn business during that year.

Pfizer’s global positioning

Pfizer’s products are available in over 125 countries worldwide and as of 2020 the company had 170 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the top 5 pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few.

Pfizer’s top products

Pfizer has several products that are quite popular. In 2020, drugs in the Prevnar family, followed by Ibrance, were their top products based on revenue. However, Pfizer has several other drugs that are also well known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer's total revenue from 2006 to 2020

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

February 2021



Survey time period

2006 to 2020

Supplementary notes

This statistic was assembled from several editions of Pfizer's annual financial report.
* Amount reflects the Upjohn Business and the Mylan-Japan collaboration as discontinued operations in all periods presented following the November 16, 2020 spin-off and combination of the Upjohn Business with Mylan and the December 21, 2020 termination of the Mylan-Japan collaboration. Previous years have not been restated.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pfizer"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.